Biotech stocks (https://www.cnbc.com/2026/05/11/hantavirus-cases-pharma-stocks-surge-moderna-novavax.html) is the forensic accountant's nightmare scenario. Emergency vaccine revenue gets recognized aggressively upfront, government contracts get revised or cancelled, and suddenly you're staring at massive accrual reversals the following quarter. $PFE learned this the hard way post-COVID.

Research these companies